Business
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
Coverage at CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States was effective July 5All three of the largest pharmacy benefit
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Coverage at CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States was effective July 5All three of the largest pharmacy benefit managers in the United States have now included ZORYVE on formulary, providing access to 80% of commercial livesZORYVE is a once-daily, steroid-free cream for adults and adolescents with plaque psoriasis, including all affected areas of the body and for long-term use WESTLAKE VILLAGE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5. These national formularies provide access to an additional 20 million commercial lives in the United States. ZORYVE is covered for individuals with plaque psoriasis and a prior history of use of a topical steroid, although no prior steroid therapy is required for individuals with plaque psoriasis in sensitive skin areas. “This is the largest U.S. pharmacy benefit manager, and the third to include ZORYVE on its national formularies since we launched less than a year ago. We have now unlocked broad high-quality access for a total of 131 million commercially insured patients, representing 80% of covered lives in the United States. Notably, in line with our access goals, more than 90% of the 130 million covered commercial patients have access to ZORYVE without a prior authorization,” said Frank Watanabe, President and CEO of Arcutis. “The placement of ZORYVE in a preferred tier position aligns with our focus on ensuring affordable access to ZORYVE so that adults and adolescents with plaque psoriasis can benefit from our effective and well-tolerated therapy.” The vast majority of individuals with plaque psoriasis use topical therapies, and until recently there were few steroid-free options. ZORYVE, a once-daily, steroid-free phosphodiesterase-4 (PDE4) inhibitor cream, provides rapid results for both hard-to-treat areas, such as knees and elbows, as well as sensitive areas, such as the face, intertriginous areas, and genitalia. In addition to working...